Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Securidrap Selfia

Research Leaders

7 sponsors active, led by University Medical Center Rostock

Related Conditions

Often studied with 14 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed2
Unknown2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT05510401Not ApplicableRecruitingPrimary

Evaluation of Safe Use of SECURIDRAP® SELFIA®

NCT03786640Completed

Abbott Brady 3T MRI PMCF

NCT04387357Unknown

Multimodal Imaging in the Study of Disorientation in the Hospital

NCT04134806Unknown

Gait Analysis by Induced Disorientation in a VR Environment

NCT02267681Phase 4Completed

Opioid Effects on Cognitive Function Following Colonoscopy

Showing all 5 trials

Research Network

Common Treatments

  • Securidrap Selfia1
  • 3t Mri Scan1
  • Alfentanil1
  • Fentanyl1
  • Propofol1

Active Sponsors

  • University Medical Center Rostock2
  • German Center for Neurodegenerative Diseases (DZNE)2
  • University of Rostock1
  • EVAMED1
  • Abbott Medical Devices1

Top Investigators

Related Conditions

  • Mild Cognitive Impairment2
  • Older Adults2
  • Behavior Disorders1
  • Mild Dementia1
  • Arrythmia1

Activity Timeline